Alliance Pharma plc (LON:APH) Earns Buy Rating from Numis Securities Ltd

Numis Securities Ltd restated their buy rating on shares of Alliance Pharma plc (LON:APH) in a research report report published on Tuesday, July 18th, MarketBeat.com reports. Numis Securities Ltd currently has a GBX 60 ($0.78) target price on the stock.

Receive News & Ratings for Alliance Pharma plc Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliance Pharma plc and related companies with MarketBeat.com's FREE daily email newsletter.

Separately, FinnCap initiated coverage on Alliance Pharma plc in a report on Tuesday, May 9th. They set a buy rating and a GBX 65 ($0.85) price target on the stock.

Alliance Pharma plc (LON:APH) opened at 51.25 on Tuesday. The company’s market cap is GBX 242.27 million. Alliance Pharma plc has a one year low of GBX 41.33 and a one year high of GBX 57.50. The stock has a 50 day moving average of GBX 52.37 and a 200 day moving average of GBX 49.72.

COPYRIGHT VIOLATION WARNING: This story was first published by [[site]] and is the sole property of of [[site]]. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at [[permalink]].

About Alliance Pharma plc

Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international.